Table 2. Antimicrobial drug susceptibility testing for Bordetella petrii isolates, by strain and strain type, October 2007–November 2008*.
Drug | FR 3799, clinical† | FR3891, clinical† | FR 3996, clinical† | FR 3497, clinical (17) | KMRW, environmental (1) | Fry et al., clinical (16)‡ | Stark et al., clinical (18) |
---|---|---|---|---|---|---|---|
Penicillin | >32 | >32 | >32 | >32 | >32 | >32 | ND |
Amoxicillin | >256 | >256 | >256 | >256 | 8 | >256 | +clav: 4 |
Piperacillin | 16 | 12 | 12 | 256 | 0.25 | ND | ND |
Piperacillin and tazobactam | 16 | 48 | 24 | 256 | 0.38 | 2 | <4 |
Cefotaxime | >32 | >32 | >32 | >32 | >32 | >32 | Ceftriax: >64 |
Ceftazidime | 48 | 256 | >256 | 2 | 4 | 32 | 16 |
Ertapenem | >32 | >32 | >32 | 0.016 | 0.047 | >32 | ND |
Imipenem | 3 | 4 | 8 | 1 | 0.75 | >32 | ND |
Meropenem | 12 | >32 | 12 | 0.023 | 0.047 | >32 | <0.25 |
Doripenem | 32 | >32 | >32 | 0.094 | 0.125 | ND | ND |
Gentamicin | 1 | 1 | 1.5 | 12 | 3 | 4 | 4 |
Tobramycin | 1 | 1 | 1 | 64 | 4 | 16 | 2 |
Amikacin | 8 | 16 | 16 | 64 | 48 | >256 | 8 |
Levofloxacin | 16 | 24 | 24 | 2 | 0.25 | ND | ND |
Ciprofloxacin | >32 | >32 | >32 | 4 | 0.38 | >32 | 2 |
Moxifloxacin | 12 | 12 | 12 | 1.5 | 0.032 | ND | ND |
Minocyclin | 0.75 | 0.75 | 0.75 | 0.5 | 0.125 | ND | ND |
Tygecyclin | 0.75 | 1 | 1 | 0.25 | 0.023 | ND | ND |
Cotrimoxazole | 0.50 | 0.50 | 0.50 | 0.012 | 0.006 | 8 | ND |
Fosfomycin | 4 | 8 | 8 | 6 | 12 | ND | ND |
Quinupristin and dalfopristin | >32 | >32 | >32 | >32 | >32 | ND | ND |
Rifampin | >32 | >32 | >32 | >32 | >32 | >32 | ND |
Daptomycin | >256 | >256 | >256 | >256 | >256 | ND | ND |
Linezolid | >256 | >256 | >256 | >256 | >256 | ND | ND |
Clindamycin | >256 | >256 | >256 | >256 | >256 | >256 | ND |
Fucidic acid | >256 | >256 | >256 | >256 | >256 | ND | ND |
*Values are MICs by Etest in μg/mL. +clav, in combination with clavulanic acid; Ceftriax, ceftriaxone tested instead of cefotaxime; ND, not determined. †This study. ‡Ampicillin was tested instead of amoxicillin.